Literature DB >> 23394701

Antiretroviral bioanalysis methods of tissues and body biofluids.

Robin DiFrancesco1, Getrude Maduke, Rutva Patel, Charlene R Taylor, Gene D Morse.   

Abstract

Research in the many areas of HIV treatment, eradication and prevention has necessitated measurement of antiretroviral (ARV) concentrations in nontraditional specimen types. To determine the knowledgebase of critical details for accurate bioanalysis, a review of the literature was performed and summarized. Bioanalytical assays for 31 ARVs, including metabolites, were identified in 205 publications measuring various tissues and biofluids. 18 and 30% of tissue or biofluid methods, respectively, analyzed more than one specimen type; 35-37% of the tissue or biofluid methods quantitated more than one ARV. 20 and 76% of tissue or biofluid methods, respectively, were used for the analysis of human specimens. HPLC methods with UV detection predominated, but chronologically MS detection began to surpass. 40% of the assays provided complete intra- and inter-assay validation data, but only 9% of publications provided any stability data with even less for the prevalent ARV in treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23394701      PMCID: PMC3836712          DOI: 10.4155/bio.12.319

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  225 in total

1.  Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

Authors:  R M van Praag; R P van Heeswijk; S Jurriaans; J M Lange; R M Hoetelmans; J M Prins
Journal:  Clin Infect Dis       Date:  2001-09-20       Impact factor: 9.079

2.  Determination of 3'-azido-2',3'-dideoxyuridine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography.

Authors:  T N Clark; C A White; C K Chu; M G Bartlett
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-05-05

3.  Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine.

Authors:  R P van Heeswijk; A I Veldkamp; J W Mulder; P L Meenhorst; J H Beijnen; J M Lange; R M Hoetelmans
Journal:  Ther Drug Monit       Date:  2001-06       Impact factor: 3.681

4.  Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

Authors:  Alain Lafeuillade; Caroline Solas; Philippe Halfon; Stéphane Chadapaud; Gilles Hittinger; Bruno Lacarelle
Journal:  HIV Clin Trials       Date:  2002 Jan-Feb

5.  Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study.

Authors:  L Zhang; R Price; F Aweeka; S E Bellibas; L B Sheiner
Journal:  Eur J Pharm Sci       Date:  2001-02       Impact factor: 4.384

6.  Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.

Authors:  B M Sadler; G E Chittick; R E Polk; D Slain; T M Kerkering; S D Studenberg; Y Lou; K H Moore; J L Woolley; D S Stein
Journal:  J Clin Pharmacol       Date:  2001-04       Impact factor: 3.126

7.  Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma.

Authors:  H L Jordan; A S Pereira; M S Cohen; A D Kashuba
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

8.  Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.

Authors:  R M van Praag; S Repping; J W de Vries; J M Lange; R M Hoetelmans; J M Prins
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

9.  Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir.

Authors:  S Taylor; D J Back; S M Drake; J Workman; H Reynolds; S E Gibbons; D J White; D Pillay
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

10.  Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.

Authors:  S Taylor; H Reynolds; C A Sabin; S M Drake; D J White; D J Back; D Pillay
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

View more
  5 in total

1.  Simultaneous determination of antiretroviral drugs in human hair with liquid chromatography-electrospray ionization-tandem mass spectrometry.

Authors:  Yan Wu; Jin Yang; Cailing Duan; Liuxi Chu; Shenghuo Chen; Shan Qiao; Xiaoming Li; Huihua Deng
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-11       Impact factor: 3.205

2.  Clinical pharmacology quality assurance for HIV and related infectious diseases research.

Authors:  R DiFrancesco; K Tooley; S L Rosenkranz; S Siminski; C R Taylor; P Pande; G D Morse
Journal:  Clin Pharmacol Ther       Date:  2013-03-26       Impact factor: 6.875

3.  Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

Authors:  Joshua Gini; Sujan Dilly Penchala; Alieu Amara; Elizabeth Challenger; Deirdre Egan; Catriona Waitt; Mohammed Lamorde; Catherine Orrell; Landon Myer; Saye Khoo; Laura J Else
Journal:  Bioanalysis       Date:  2018-11-19       Impact factor: 2.681

Review 4.  Tandem mass spectrometry of small-molecule antiviral drugs: 1. HIV-related antivirals.

Authors:  W M A Niessen
Journal:  Int J Mass Spectrom       Date:  2020-06-15       Impact factor: 1.986

5.  Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.

Authors:  Tulsidas Mishra; Pranav S Shrivastav
Journal:  ScientificWorldJournal       Date:  2014-01-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.